Key Highlights
- India’s Sun Pharmaceutical Industries has submitted an all-cash $13 billion takeover proposal for Organon (OGN)
- This transaction would represent Sun Pharma’s biggest acquisition to date, backed by financing from JP Morgan, MUFG, and Citi
- OGN shares surged approximately 25% during Friday’s trading session, building on a 20% year-to-date rally
- Additional bidders including Grünenthal and EQT have submitted competing acquisition proposals
- The latest $13 billion proposal exceeds Sun Pharma’s earlier $12 billion bid from earlier this month
Shares of Organon (OGN) experienced a dramatic rally of over 25% Friday following reports that India’s Sun Pharmaceutical Industries has prepared a $13 billion all-cash acquisition proposal for the women’s healthcare specialist.
The Economic Times broke the story Thursday evening, referencing sources with knowledge of the negotiations. OGN shares climbed approximately 8% during afterhours trading before continuing their ascent throughout Friday’s regular session.
When the initial report surfaced, Organon carried a market capitalization of merely $2.2 billion. The proposed $13 billion acquisition price would constitute a substantial premium over the company’s recent trading levels.
Should the transaction close, it would mark Sun Pharma’s most significant acquisition in company history. The all-cash structure is reportedly backed by complete financing commitments from JP Morgan, MUFG, and Citi.
Sun Pharma intends to integrate Organon into its current business structure. The proposed transaction would not involve issuing Sun Pharmaceutical equity to existing Organon shareholders.
This represents Sun Pharma’s second attempt to acquire the company. Reports from earlier in the month indicated the Indian pharmaceutical manufacturer submitted a $12 billion proposal. The newly reported $13 billion offer represents a billion-dollar increase within just weeks.
Competing Bids Emerge
Sun Pharma faces competition in its pursuit of Organon. Germany-based pharmaceutical company Grünenthal and Swedish private equity player EQT have each reportedly submitted their own acquisition proposals.
The competitive bidding environment underscores the attractiveness of Organon’s product lineup — an extensive collection of pharmaceuticals and therapies concentrated primarily on women’s healthcare, complemented by its American manufacturing capabilities.
Organon emerged as an independent entity through a spinoff from Merck in June 2021. The stock has experienced significant volatility since then, declining roughly 30% over the trailing 12 months despite Friday’s substantial upward movement.
Unusual Trading Activity
News of the potential acquisition sparked exceptional trading activity. Approximately 5.2 million OGN shares traded hands within the opening hours of Friday’s session — nearly equivalent to the entire three-month average daily volume of 5.9 million shares.
Friday’s 25.47% surge elevated the stock’s year-to-date performance to a 20.25% gain.
OGN traded above the $9.20 per share level in Thursday’s afterhours session, representing a significant increase from its comparatively modest $2.2 billion market capitalization at Thursday’s close.
Neither Sun Pharma nor Organon had issued official statements confirming any transaction agreement as of Friday afternoon.
